Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

NetScientific provides more backing for cancer immunotherapies developer

The transatlantic healthcare IP commercialisation group has upped its stake in PDS Biotechnology
Stop prostate cancer
PDS's cancer treatment pipeline includes compounds for prostate, ovarian, breast and colorectal cancers

NetScientific PLC (LON:NSCI) has upped its stake in PDS Biotechnology, a developer of cancer immunotherapies and vaccines for infectious diseases.

The Aim-listed firm exercised warrants for 1.39mln shares at a cost of US$687,493.

NetScientific has now invested a total of US$3.5ln in PDS Biotechnology, giving it a 14.6% stake.

PDS is operating in the exciting area of immuno-oncology – activating the body's own immune system to recognise and destroy cancer cells.

The field has caused a lot of excitement in the medical world, but one of the major drawbacks has been reports of debilitating toxicities – a drawback PDS has conquered with its Versamune T-cell (a type of white blood cell) activating platform.

PDS's cancer treatment pipeline includes compounds for prostate, ovarian, breast and colorectal cancers, in addition to its lead PDS0101 programme for several HPV-related cancers – HPV, or human papillomavirus, being a virus that infects the skin and the cells lining body cavities.

PDS has positive phase I/IIa trial data under its belt and has agreed partnership funding from the National Institute of Health and MD Anderson for three phase II clinical trials.

Shares in NetScientific rose 2.3% to 67p on the news.

John-H.jpg
Why Invest In Netscientific PLC? Read More Here

Register here to be notified of future NSCI Company articles
View full NSCI profile

Netscientific PLC Timeline

Related Articles

Bankroll.jpg
March 01 2017
The new funds will be used to expand the pre-clinical and early-clinical development of the company’s immuno-oncology drug, Clevegen
picture of drug research
February 20 2017
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.
Blood test
September 27 2016
The group has ambitions to strengthen its transatlantic focus through organic and strategic growth

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use